SCHEMBL1876191

SCHEMBL1876191

c1ccc(Sc2nc3ccccc3s2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.66
ALDH1A1 P00352 5/20 0.66
HSD17B10 Q99714 5/20 0.66
FBP1 P09467 3/20 0.66
ALOX15 P16050 3/20 0.66
ADRA2A P08913 1/20 0.66
ADORA3 P0DMS8 1/20 0.66
DRD2 P14416 1/20 0.66
ADRA2B P18089 1/20 0.66
ADRA2C P18825 1/20 0.66
DRD1 P21728 1/20 0.66
MC5R P33032 1/20 0.66
OPRM1 P35372 1/20 0.66
DRD3 P35462 1/20 0.66
OPRK1 P41145 1/20 0.66
CCR2 P41597 1/20 0.66
HTR6 P50406 1/20 0.66
SLC6A3 Q01959 1/20 0.66
PDK1 Q15118 1/20 0.66
TDP1 Q9NUW8 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11632405 0.90 FBP1 (0.56) HPGDALDH1A1HSD17B10FBP1ALOX15
SCHEMBL381557 0.88 ALDH1A1 (0.76) HPGDALDH1A1HSD17B10FBP1ALOX15
SCHEMBL30005981 0.88 ALDH1A1 (0.76) HPGDALDH1A1HSD17B10FBP1ALOX15
SCHEMBL31038109 0.86 FBP1 (0.58) HPGDALDH1A1HSD17B10FBP1ALOX15
SCHEMBL31038108 0.86 FBP1 (0.58) HPGDALDH1A1HSD17B10FBP1ALOX15
SCHEMBL11333963 0.86 FBP1 (0.74) HPGDALDH1A1HSD17B10FBP1ALOX15
SCHEMBL8563621 0.86 FBP1 (0.58) HPGDALDH1A1HSD17B10FBP1ALOX15
SCHEMBL31038096 0.86 FBP1 (0.74) HPGDALDH1A1HSD17B10FBP1ALOX15
SCHEMBL8561692 0.86 HPGD (0.58) HPGDALDH1A1HSD17B10FBP1ALOX15
SCHEMBL8363011 0.86 FBP1 (0.58) HPGDALDH1A1HSD17B10FBP1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060223320-A1 Polishing technique to minimize abrasive removal of material and composition therefor FREESCALE SEMICONDUCTOR, INC. 2006-10-05 US claimed
US-5283016-A Method for preparing photosensitive microcapsules THE MEAD CORPORATION (US) 1994-02-01 US claimed
US-20230089368-A1 POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) 2023-03-23 US disclosed
EP-3999057-A1 POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES ANAGENESIS BIOTECHNOLOGIES SAS (FR) 2022-05-25 EP disclosed
CN-114144410-A Polyarylurea derivatives and their use in the treatment of muscular diseases 阿纳格纳斯生物技术股份有限公司 2022-03-04 CN disclosed
US-20210228550-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS 2021-07-29 US disclosed
US-10945996-B2 Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) 2021-03-16 US disclosed
US-20190209531-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS 2019-07-11 US disclosed
US-20180000793-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis ABEL-SANTOS ERNESTO (US) 2018-01-04 US disclosed
WO-2016127102-A2 INHIBITING GERMINATION OF CLOSTRIDIUM PERFRINGENS SPORES TO REDUCE NECROTIC ENTERITIS ABEL-SANTOS ERNESTO (US) 2016-08-11 WO disclosed
US-20150266836-A1 AROMATIC SULFIDE COMPOUNDS AND METHODS AND USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-09-24 US disclosed
WO-1999032106-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER CORPORATION (US) 1999-07-01 WO disclosed
WO-1999032455-A1 INHIBITION OF RAF KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS BAYER CORPORATION (US) 1999-07-01 WO disclosed
US-RE35135-E Dental material; mixture of radical-polymerizable monomer, alpha-ketocarbonyl and aromatic amine MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1995-12-26 US disclosed
US-5091033-A ADHESIVE FOR CERAMICS AND PROCESSES FOR THE BONDING OF CERAMICS USING SAME MITSUI SEKIYU KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1992-02-25 US disclosed
EP-0136186-B1 PHOTOCURABLE RESIN COMPOSITION MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1989-09-06 EP disclosed
EP-0252603-A2 Adhesives for ceramics and processes for the bonding of ceramics using same MITSUI SEKIYU KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-01-13 EP disclosed
US-4548689-A RADICAL POLYMERIZABLE MONOMER, KETOCARBONYL COMPOUND AND MERCAPTOB MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1985-10-22 US disclosed
EP-0136186-A2 Photocurable resin composition MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1985-04-03 EP disclosed
US-4245033-A AN ORGANIC SILVER SALT, A HALIDE AND A SULFUR COMPOUND EXPOSED TO FORM A SILVER IMAGE OF HIGH CONTRAST AND STABILITY CANON KABUSHIKI KAISHA (JP) 1981-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10945996-B2 Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis CASP3, SI, PYCARD HPGD 785/4885ALDH1A1 4772/4885HSD17B10 2302/4885
US-20150266836-A1 AROMATIC SULFIDE COMPOUNDS AND METHODS AND USE THEREOF AHR, CBS, ARSA HPGD 1241/4885ALDH1A1 83/4885HSD17B10 1060/4885
US-20230089368-A1 POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES CKMT1A; CKMT1B, TNNC1, UBQLN2 HPGD 1280/4885ALDH1A1 1264/4885HSD17B10 1200/4885
US-20190209531-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis CASP3, SI, PYCARD HPGD 785/4885ALDH1A1 4772/4885HSD17B10 2302/4885
US-20210228550-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis CASP3, SI, PYCARD HPGD 785/4885ALDH1A1 4772/4885HSD17B10 2302/4885
US-20180000793-A1 Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis CASP3, SI, PYCARD HPGD 785/4885ALDH1A1 4772/4885HSD17B10 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.